Skip to main content

Betty Yan is co-head of the Life Sciences Transaction practice. She advises pharmaceutical, biotech and other life sciences companies in a broad range of corporate, operational and transactional matters. Providing both a legal and business perspective, she assists clients in new entity formation and corporate restructuring; drafting and negotiating industry specific agreements (including manufacture and supply, distribution, research and development, technology transfer, and clinical trial agreements); complex M&A transactions involving single product, product line, business divisions, facilities, and corporate entities; and structuring strategic alliances, joint ventures, collaborations (including co-promotion and co-commercialization), and licensing arrangements.

Prior to entering private practice, she was in-house counsel at The Chase Manhattan Bank, where she represented its diversified industry group (which included the health care industry) in complex finance arrangements and was seconded to the bank's Hong Kong office.


  • Pharmaceutical company in its acquisition of worldwide rights, including associated intellectual property rights, to a line of oral care products.
  • Pharmaceutical company in the FTC-mandated divestiture of veterinarian vaccines in order for it to complete its acquisition of another pharmaceutical company.
  • Pharmaceutical company in divesting basket of pharmaceutical products, including IP licensing and exclusive supply arrangements.
  • Pharmaceutical company in divesting a prescription subpart H drug, consisting of upfront purchase price, earn-out and equity in the acquiring company.
  • Joint venture entity (between a pharmaceutical company and consumer product company) in divesting a topical product it developed.
  • UK pharmaceutical company in divesting its US subsidiary, including a manufacturing facility for controlled substance and licensing of IP assets held by parent and affiliate companies.
  • Generic manufacturer in acquiring seven hematology products and establishing innovator arm for it.
  • Generic manufacturer in the sale of its dermatology business to a venture-backed company, including sale of manufacturing facility and negotiation of a complex commercial arrangement for the ongoing operation of the business until certain licensures were issued to the buyer.
  • Generic manufacturer in the sale of multiple manufacturing facilities located within the US, including transitional supply agreement for supply of seller’s products.
  • Pharmaceutical company in hybrid license and sale transaction wherein assets were licensed to buyer in order for the parties to jointly complete development of the asset and sale to buyer once certain development milestones were met.


LMG Life Sciences Guide
"Life Sciences Star"—Mergers & Acquisitions (2022)
"Life Sciences Star"—Licensing & Collaboration (2022)
NJ Law Journal
Diverse Attorneys of the Year (2021)
New Jersey Law Journal
New Jersey Trailblazers (2020)



  • J.D./M.B.A., Fordham University, 1992
  • B.A., University of Pennsylvania, 1988


  • New York
  • New Jersey


  • Member, New Jersey Bar Association Ethics Committee for Mercer County
  • Member, Asian Pacific American Lawyers Association of New Jersey


  • Chinese (Cantonese)